Bioverativ (NASDAQ: BIVV) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Bioverativ to related businesses based on the strength of its institutional ownership, earnings, profitability, dividends, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

93.5% of Bioverativ shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Bioverativ and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bioverativ $887.40 million $439.60 million 12.07
Bioverativ Competitors $284.30 million $34.29 million 127.03

Bioverativ has higher revenue and earnings than its peers. Bioverativ is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Bioverativ and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bioverativ 40.44% 69.03% 40.94%
Bioverativ Competitors -5,297.45% -431.37% -39.69%

Analyst Recommendations

This is a summary of recent ratings for Bioverativ and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bioverativ 1 8 6 1 2.44
Bioverativ Competitors 837 3186 11555 230 2.71

Bioverativ currently has a consensus target price of $60.36, indicating a potential upside of 22.28%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.78%. Given Bioverativ’s peers stronger consensus rating and higher probable upside, analysts clearly believe Bioverativ has less favorable growth aspects than its peers.


Bioverativ beats its peers on 7 of the 11 factors compared.

Bioverativ Company Profile

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with's FREE daily email newsletter.